Loading…

Design, synthesis and biological evaluation of coumarin coupled nitroimidazoles as potential imaging agents

Solid tumors contain regions of hypoxia in comparison to normal tissues. The nitroimidazoles have shown great promise for targeting different types of cancers. The present work involves the design, syntheses, and in vitro and in vivo investigations of hypoxia targeted nitroimidazole radioconjugates...

Full description

Saved in:
Bibliographic Details
Published in:RSC advances 2015-01, Vol.5 (118), p.9712-97112
Main Authors: Saini, Nisha, Varshney, Raunak, Tiwari, Anjani K, Kaul, Ankur, Ishar, M. P. S, Mishra, Anil K
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Solid tumors contain regions of hypoxia in comparison to normal tissues. The nitroimidazoles have shown great promise for targeting different types of cancers. The present work involves the design, syntheses, and in vitro and in vivo investigations of hypoxia targeted nitroimidazole radioconjugates (2NIHC and 4NIHC). Flow cytometry analysis showed that the normoxic-hypoxic mean fluorescence of 2NIHC is 10 fold greater than that of 4NIHC and much higher than that of the well-known pimonidazole hypoxia marker. Furthermore, molecular modeling studies of these ligands with CK2α revealed that 2NIHC is a more potential CK2α inhibitor due to π-π interactions and H-bonding with Val116, Glu114, Asp175, Asn161 and His160 in the active pockets of the target. Radio labeling yields for both the complexes with 99m Tc were >98%. Biodistribution in EAT tumor bearing mice demonstrated rapid clearance of 99m Tc-2NIHC and high T/M ratio (3.57% ID/g) as compared to 99m Tc-4NIHC (2.05% ID/g) at 4 h. IC 50 values of both ligands were estimated by MTS in different cell lines in addition to tumor regression studies. Solid tumors contain regions of hypoxia in comparison to normal tissues. The nitroimidazoles have shown great promise for targeting different types of cancers.
ISSN:2046-2069
2046-2069
DOI:10.1039/c5ra17907f